Drug Database
GA

gallium (68Ga)-edotreotide (NETSPOT)

✓ Approved

Cardinal Health, Inc. · SSTR2 · 影像药物

什么是 gallium (68Ga)-edotreotide?

gallium (68Ga)-edotreotide 是一种影像药物,由Cardinal Health, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Others。

药物档案

商品名NETSPOT
公司Cardinal Health, Inc.
药物类别影像药物
分子靶点SSTR2
给药途径Others
状态Approved

作用机制

分子靶点

gallium (68Ga)-edotreotide 作用于 1 个分子靶点:

SSTR2somatostatin receptor 2 (SST2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

gallium (68Ga)-edotreotide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

相关研究文献

PubMedRespiratory research2026-11-17

68Ga-FAPI-04 PET/CT: a new horizon for evaluating pulmonary involvement in MDA5+ dermatomyositis.

Wu Yinlan Y, Li Yanhong Y, Zhang Wenjie W, Zhao Zhen Z et al.

MDA5+ dermatomyositis (MDA5+DM) frequently complicates interstitial lung disease (ILD), especially rapidly progressive ILD (RP-ILD), which worsens prognosis. Traditional assessments cannot directly reflect fibroblast activation status, a key driver of pulmonary fibrosis. 68Ga-FAPI-04 PET/CT targets fibroblast activation protein (FAP), but its value in MDA5+DM remains understudied. Fourteen MDA5+DM patients and 5 controls were enrolled. 68Ga-FAPI-04 PET/CT was performed to obtain SUVmax of lungs, muscles, and other organs. Clinical data, pulmonary function tests, and deep learning-quantified HRCT indices were collected. Follow-ups for pulmonary function and HRCT were conducted. Correlations between SUVmax, clinical features, and follow-up outcomes were analyzed. Whole-lung SUVmax was significantly higher in MDA5+DM patients (3.32 vs. 0.67, p < 0.0001), with left lower lobe showing the most prominent difference (p = 0.0003). SUVmax strongly correlated with HRCT inflammation/fibrosis indices (e.g., left lower lobe vs. PII at 3 months: r = 0.9863, p < 0.0001) and small-to-medium airway function (lung vs. MMEF 75/25: r=-0.8168, p = 0.0133). Baseline SUVmax predicted 3-12-month lesion progression and lung function changes, with deceased patients having higher baseline whole-lung SUVmax (p = 0.008). This exploratory study suggests that 68Ga-FAPI-04 PET/CT may reflect fibroblast activation and the active inflammatory-fibrotic process, assesses early pulmonary impairments and monitoring lesion progression in MDA5+DM. It provides a valuable hypothesis-generating tool for clinical evaluation, warranting further validation.

PMID 43040325
阅读全文 →
PubMedScientific American2026-11-17

Mud for the War Machine: The U.S. needs gallium for its weapons, and nearly all of it comes from China. Now the Pentagon is paying to pull the metal out of a mountain of red mud in Louisiana.

Scoles Sarah S

PMID 43043163
阅读全文 →
PubMedACS applied materials & interfaces2026-11-17

Electron-Rich Cobalt Single-Atom Sites via Axial GaN Coordination Boost CO2-to-CO Conversion through an Optimized *COOH Pathway.

Wang Caiyue C, Huang Bo B, Zhang Yingzheng Y, Feng Wuyi W et al.

Precise tuning of the electronic structure of single-atom metal sites at their atomic scale to surpass their intrinsic activity and selectivity limits remains a fundamental challenge. Here, we constructed a well-defined electron-rich single-atom Co site by loading cobalt phthalocyanine (CoPc) molecules with CoN4 centers onto the gallium nitride (GaN) substrate (CoPc@GaN). Characterization analysis reveals that the work function difference between the GaN substrate and CoPc induces an interfacial built-in electric field (BEF), which drives electron transfer from GaN to the CoN4 center, forming electron-rich Co active sites. This configuration effectively optimizes the adsorption/dsorption behavior of reaction intermediates (*COOH and *CO) during CO2RR. In the H-type cell, CoPc@GaN achieves a CO Faradaic efficiency of 97.9% at -0.9 V (vs RHE), while in a flow cell, the efficiency increases to 98.8% at -1.0 V (vs RHE). The electrocatalyst maintains >90% selectivity across a broad potential window of 1000 mV and demonstrates stable performance over 32 h. In situ attenuated total reflection Fourier transform infrared spectroscopy (ATR-FTIR) and density functional theory (DFT) calculations further reveal that the electron-rich Co active sites significantly reduce the energy barrier for *COOH formation and facilitate CO desorption, validating the feasibility of the strategy of modulating metal phthalocyanines through substrate engineering.

PMID 43039873
阅读全文 →
PubMedApplied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine2026-11-16

Comparative analysis of ANN and nuclear code predictions for neutron-induced reactions on Ga and As isotopes.

Siddik Tarik T

This study evaluates the application of Artificial Neural Networks (ANNs) as a data-driven tool for estimating neutron-induced reaction cross-sections for gallium and arsenic isotopes. Specifically, the model was applied to the 69Ga(n,p)69mZn, 69Ga(n,2n)68Ga, 71Ga(n,p)71Zn, 71Ga(n,2n)70Ga, 75As(n,2n)74As, and 75As(n,p)75Ge reactions. The ANN model's performance was evaluated by comparing its numerical approximations with experimental data from the EXFOR database and with benchmarks from the nuclear reaction codes EMPIRE-3.2 Malta and TALYS 1.9 in their standard configurations. The results demonstrate that the ANN model exhibits a high degree of statistical alignment with the experimental datasets, yielding lower residual errors than the evaluated theoretical codes within the training energy ranges. These findings suggest that the ANN serves as an effective complementary tool for data evaluation and interpolation, providing a precise statistical representation of experimental trends that can supplement traditional phenomenological modeling in nuclear science and technology.

PMID 43035067
阅读全文 →
PubMedEJNMMI reports2026-11-16

Dual-tracer 68Ga-PSMA and 68Ga-FAPI PET/CT characterization of solitary testicular metastasis from castration-resistant prostate cancer.

Zhou Huijun H, Sun Duo D, Li Lin L, Hacker Marcus M et al.

Testicular metastasis from prostate cancer is extremely rare. We report a case of solitary testicular metastasis detected by dual-tracer PET/CT using 68Ga-PSMA and 68Ga-FAPI in a patient with castration-resistant prostate cancer. A 66-year-old man with a history of prostate adenocarcinoma developed biochemical progression after prior therapies. 68Ga-PSMA PET/CT revealed a solitary PSMA-avid testicular lesion with no significant uptake in the prostate bed. Subsequent 68Ga-FAPI PET/CT demonstrated concordant intense uptake in the same lesion, while the primary site remained negative. The patient underwent orchiectomy, and histopathological examination confirmed metastatic prostate cancer. This case highlights a rare pattern of solitary testicular metastasis from castration-resistant prostate cancer detected by dual-tracer PET/CT. The concordant uptake of 68Ga-PSMA and 68Ga-FAPI in the metastatic lesion suggests complementary information regarding tumor characteristics and the associated tumor microenvironment. Dual-tracer PET imaging may provide additional value for the characterization of atypical metastatic lesions.

PMID 43035622
阅读全文 →
PubMedEJNMMI radiopharmacy and chemistry2026-11-16

Fully automated [68Ga]Ga-FAPI-46 radiosynthesis using GalliAd® generator and MiniAIO® synthesizer: development and validation for PET imaging of fibroblast activation protein.

Deschavannes Arnaud A, Jacquet-Francillon Nicolas N, Piquemal Marie M, Flaus Anthime A et al.

Fibroblast activation protein (FAP) is a membrane-bound serine protease that is selectively overexpressed on cancer-associated fibroblasts (CAFs) in more than 90% of epithelial tumors. [68Ga]Ga labeled FAP inhibitors (FAPI) have emerged as promising PET tracers for oncological imaging and theranostic applications. [68Ga]Ga-DOTA-FAPI-46 (simplified as [68Ga]Ga-FAPI-46) is a DOTA-chelated FAPI that demonstrates superior tumor retention compared to earlier FAPI compounds. We describe the development, optimisation, and pharmaceutical validation of a combination not previously reported for the production of this radiopharmaceutical: a fully automated, one-step radiosynthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate, performed at the hospital radiopharmacy of the Groupement Hospitalier Sud, Hospices Civils de Lyon, in the context of a clinical trial (EudraCT 2025-524897-40-00). Radiolabeling was performed via a miniAIO automated synthesizer (Trasis) and a GalliAd [68Ge]Ge/[68Ga]Ga generator (IRE-Elit). The process generator elution, direct radiolabeling at 95 °C for 7 min in sodium acetate buffer with L-ascorbic acid, HLB solid-phase purification and 0.22 μm sterilizing filtration was performed in a single uninterrupted automated sequence. The quality control testing included release tests (visual appearance, final volume, radioactivity, pH, radiochemical purity by radio-TLC and radio-HPLC, radionuclidic identity, filter integrity, and bacterial endotoxin testing), post-release tests (radionuclidic purity and sterility), and validation batch-only tests (L-ascorbic acid and ethanol content). Analytical methods were validated as per ICH Q2(R2). All the validation batches met the predefined release and post-release specifications. The decay-corrected radiochemical yields ranged from 66.9% to 86.0%, with a total synthesis time of 20 min. Radiochemical purity exceeded the acceptance threshold of 95.0% by radio-TLC and radio-HPLC at release. It remained ≥ 95.0% after 3 h for both control methods. No radiolytic impurities were detected. Radionuclidic purity was confirmed with [68Ge]Ge breakthrough < 0.001%, and the measured half-life values (66.0-69.0 min) were consistent with those of [68Ga]Ga. Endotoxin levels were < 1.0 IU/ml and all batches were sterile. Ethanol (43.6 ± 2.4 mg/ml - 5.5 ± 0.3% v/v) and L-ascorbic acid (7.5 ± 1.4 g/l) contents complied with predefined specifications. All analytical methods fulfilled the ICH Q2(R2) criteria, demonstrating adequate specificity, sensitivity and reproducibility. A fully validated one-step automated radiosynthesis of [68Ga]Ga-FAPI-46 was established via the use of a miniAIO synthesizer with a [68Ge]Ge/[68Ga]Ga generator. The process consistently produced a high-quality radiopharmaceutical suitable for clinical implementation and IMPD submission in FAP-targeted PET imaging. Trial registration EudraCT No 20,255,248,974,000 Clinical trials registry NCT07313033 15/01/2026.

PMID 43037918
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多gallium (68Ga)-edotreotide